BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29040544)

  • 1. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
    Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
    Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
    Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
    J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
    Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
    Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
    Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
    Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
    Adam D; Bilodeau C; Sognigbé L; Maillé É; Ruffin M; Brochiero E
    J Cyst Fibros; 2018 Nov; 17(6):705-714. PubMed ID: 29661510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
    Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
    J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
    Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
    Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
    Lin WY; Sohma Y; Hwang TC
    Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease.
    Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level.
    Cui G; Stauffer BB; Imhoff BR; Rab A; Hong JS; Sorscher EJ; McCarty NA
    Sci Rep; 2019 Sep; 9(1):13460. PubMed ID: 31530897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.